Cecelia Health LifeScan and Cecelia Health Sign Expanded Multi-Year Partnership to Offer Live Diabetes Telehealth Support in Combination with OneTouch® Solutions Integrated Holistic Health Tools and OneTouch® Blood Glucose Monitoring
Capillary Biomedical “Feasibility of an Investigational Extended Wear Infusion Set for Insulin Pump Therapy (IPT) in People with Type 1 Diabetes Mellitus.” presented at ADA’s 81st Scientific Sessions
Capillary Biomedical Reports Best-in-Class Clinical Feasibility Results for its SteadiFlow Seven-Day-Wear Infusion Set Technology at ADA Scientific Sessions
Bigfoot Biomedical® Acquires Assets of Common Sensing Bigfoot Biomedical announced today that it has acquired the intellectual property assets of Common Sensing, a Cambridge, MA-based company that develops and manufactures data-driven hardware and software solutions for people using injectable medicine, including Gocap.
Bigfoot Biomedical®Receives FDA Clearance for Bigfoot Unity™ Diabetes Management System, Featuring First-of-its-Kind Smart Pen Caps for Insulin Pens used to Treat Type 1 and Type 2 Diabetes
Illuminare Biotechnologies Novel Nerve Visualization Investigational Fluorophore Receives FDA IND Approval for First-In-Human Trial
Cecelia Health Study Finds Mental Health Has Been A Bigger Concern for People Living with Diabetes than Diabetes Itself During Covid-19
Bigfoot Biomedical® Secures up to $57 Million in Combined Debt and Equity Financing from Madryn Asset Management
Validation Institute certifies that Cecelia Health diabetes program is proven to reduce A1C
Level 2 outcomes certification validates impressive results of Cecelia Health’s diabetes management program.
Cecelia Health Diabetes Management Program Receives Association of Diabetes Care & Education Specialists (ADCES) Accreditation
Diabetes Education Accreditation Program (DEAP) certification underscores Cecelia Health’s commitment to providing superior care management programs to individuals living with diabetes.
LifeScan Partners with Cecelia Health to Provide Personalized Diabetes Health Management Coaching for OneTouch® Consumers
Coaching allows OneTouch consumers to have meaningful one-on-one interactions with clinicians to drive positive behavior change for people with diabetes and related conditions to live their best lives
Capillary Biomedical Receives $1.5 Million from Helmsley Charitable Trust for Clinical Trials of New Insulin Infusion Technology
Funding to fuel testing of extended-wear SteadiFlow technology designed to reduce infusion site failures and improve quality of life for people with diabetes
Cecelia Health closes $13 million Series B, Rittenhouse’s Saul Richter and Endo Investors’ Eric Edidin to join board of directors, number of members now exceeds 150,000.
EY Announces David Weingard of Cecelia Health as an Entrepreneur Of The Year® 2020 New York Award Finalist.
Helmsley Awards $5 Million to Evaluate Virtual Diabetes Specialty Clinic Model.
Mellitus Health Names Steve Wubker Chief Executive Officer.
Bigfoot Biomedical® Closes Series C Financing with $55 Million as Company Readies for FDA Submission of Bigfoot Unity. Funding to Support its Breakthrough Therapy and Telemedicine Solutions for People Living with Insulin-Requiring Type 1 and Type 2 Diabetes
Bigfoot Biomedical® announces coo role and executive promotions as product launch nears. New structure readies company for anticipated launch of Bigfoot Unity™ Diabetes Management Program.
Bigfoot Biomedical® Appoints Jim Malone MD Chief Medical Officer
Recognized endocrinologist and clinical researcher joins biotech start-up as company readies for submission of its innovative approach to diabetes management.
Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions
Intranasal Glucagon Could be the First Needle-Free Rescue Treatment
for Severe Hypoglycemia.
ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1
ILiAD Biotechnologies Announces Presentation of Positive Phase 2b Data for Next Generation Pertussis Vaccine at World Vaccine Congress.
Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes.
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes.
Trividia Health and Mellitus Health Partner to Develop Diabetes Care Products and Services for Pharmacies.
Mellitus Health and Glooko Announce Insulin-Dosing Software Integration Agreement.